Research and Markets: Turkey Pharmaceuticals and Healthcare Report Q2 2009

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/8b21e9/turkey_pharmaceuti) has
announced the addition of the "Turkey Pharmaceuticals and Healthcare Report Q2
2009" report to their offering.

Turkey Pharmaceuticals and Healthcare Report provides independent forecasts and
competitive intelligence on Turkey's pharmaceuticals and healthcare industry.

Outside the BRIC (Brazil, Russia, India, China) states, Turkey is considered one
of the key growth pharmaceutical markets globally. Growth has been rapid in
recent years, with per capita spending reaching US$159 in 2008, a similar level
to other emerging countries in Eastern Europe. The country's large, ageing and
increasingly urbanised population, means both demand and access to medicines
should increase in the future. Over the next five years, sales of
pharmaceuticals, which include prescription drugs and over-the-counter (OTC)
medicines, will increase from US$11.3bn to US$19.5bn, representing a compound
annual growth rate (CAGR) of 11.6%.

Despite positive market and environmental dynamics, Turkey ranks only fifth in
the Pharmaceutical Business Environment Rankings for Q209. The core reasoning
behind this is the still considerable risks present in operating in the country.
A negative regulatory climate is a key drawback for multinationals. Delays in
bringing products to market, unfavourable pricing regimes and poorly enforced
intellectual property regulations are some of the problems associated with
operating in Turkey at present. Furthermore, policy continuity, bureaucracy and
the legal framework remain key concerns.

Legislation for the creation of a universal healthcare system was enforced in
late 2008. The universal health insurance scheme includes: compulsory
participation with income-based contributions; subsidies or free coverage for
the disadvantaged or those under 18 years of age; the use of public/private
partnerships (PPPs) for providing care; and differentiated co-payment rates
between primary, secondary and tertiary care. The implementation of this
throughout 2009 will give a key indicator as to the potential for increased
pharmaceutical and health expenditure.

Perceived opportunities to capitalise on growing healthcare expenditure have led
to multinational investment in private healthcare facilities in recent years.
However, credit-driven investments - in an increasingly tight lending
environment - along with caps on top-up charges for regular services, appear to
have resulted in the accumulation of large levels of debt. While the longer term
outlook for private hospitals is positive, up to US$3bn is said to be owed by
facilities, which could lead to significant difficulties for some operations in
2009.

The Burden of Disease Database (BoDD) reveals that development of the healthcare
service is having a positive effect on the country's disease profile.
Disability-adjusted life years (DALYs) lost to all diseases and injuries are
steadily declining in the country. In 2008 Turkey was placed 66th globally in
terms of per capita DALYs. The obvious trend seen by improved access to care is
the decreasing burden of communicable diseases, which we forecast to fall by 46%
over 2008-2030. Meanwhile as the country becomes increasingly Westernised,
non-communicable diseases will continue to increase. This will be reflected in
pharmaceutical sales, with cardiovascular treatments rising and anti-infectives
falling through to 2013.

Key Topics Covered:

* SWOT Analysis.
* Turkey Pharmaceuticals And Healthcare Industry SWOT
* Turkey Political SWOT
* Turkey Economic SWOT
* Turkey Business Environment SWOT.
* Pharmaceutical Business Environment Rating
* Regional Pharma Business Environment Ratings
* Limits Of Potential Returns
* Risks To Realisation Of Returns
* Turkey - Market Summ
* Regulatory Regime.
* Intellectual Property Regime
* Intellectual Property Shortcomings
* Counterfeit Drugs
* Pricing Regime

Companies Mentioned:

* Novartis
* Sanofi-Aventis
* GlaxoSmithKline
* Pfizer
* Roche
* AstraZeneca
* Bayer
* Merck & Co
* Abdi Ýbrahim
* Eczacibasi
* Pharmaceuticals
* Sanovel Pharmaceuticals
* EastPharma (formerly Deva Holding)
* Actavis (formerly Fako)
* Biomeks

For more information visit
http://www.researchandmarkets.com/research/8b21e9/turkey_pharmaceuti

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009